PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

Trial PAR008 is on ANZCTR, page-46

  1. 1,577 Posts.
    lightbulb Created with Sketch. 165
    The Lorecivivint trial Phase 3 trial results due
    soon will be interesting. They are expecting
    DMOAD activity. At this stage of the game it
    would appear to be our biggest threat.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.